<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7F71BABD-BB5E-465A-A468-AD99CA3C8DA6"><gtr:id>7F71BABD-BB5E-465A-A468-AD99CA3C8DA6</gtr:id><gtr:name>Bandim Health Project (BHP)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/6083E7FB-0220-4F5F-97B0-7F6113B49A0C"><gtr:id>6083E7FB-0220-4F5F-97B0-7F6113B49A0C</gtr:id><gtr:name>MRC Unit, The Gambia</gtr:name><gtr:address><gtr:line1>MRC Laboratories, The Gambia</gtr:line1><gtr:line2>Atlantic Road PO Box 273</gtr:line2><gtr:line4>Fajara</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Gambia</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6083E7FB-0220-4F5F-97B0-7F6113B49A0C"><gtr:id>6083E7FB-0220-4F5F-97B0-7F6113B49A0C</gtr:id><gtr:name>MRC Unit, The Gambia</gtr:name><gtr:address><gtr:line1>MRC Laboratories, The Gambia</gtr:line1><gtr:line2>Atlantic Road PO Box 273</gtr:line2><gtr:line4>Fajara</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Gambia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7F71BABD-BB5E-465A-A468-AD99CA3C8DA6"><gtr:id>7F71BABD-BB5E-465A-A468-AD99CA3C8DA6</gtr:id><gtr:name>Bandim Health Project (BHP)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/2FEA791E-5E6C-4FD9-A97C-98EAEE9A1096"><gtr:id>2FEA791E-5E6C-4FD9-A97C-98EAEE9A1096</gtr:id><gtr:firstName>Hilton</gtr:firstName><gtr:surname>Whittle</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U190088488"><gtr:id>DEFD1AA4-37CC-4186-8D3D-16AB1104B9A7</gtr:id><gtr:title>Two Dose E-Z Measles Vaccine Trial: Boosting Of Immune Responses In Bissau</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U190088488</gtr:grantReference><gtr:abstractText>Millions of children are given a booster dose of measles vaccine in mass immunisation campaigns throughout the world. It is not know if the rapidity of responses, which is likely to relate to protection against measles, varies according to the number of doses of measles vaccine the children have previously been given. We will compare these responses in children who have been part of previous trial of one or two doses of measles vaccine in Guinea Bissau.</gtr:abstractText><gtr:technicalSummary>Little is known of short term antibody responses following a booster dose of measles vaccine in immunized children. We will compare the magnitude of these responses in three year old children who have received one or two doses of Edmonston-Zagreb vaccine in infancy as part of a previous trial in Bissau. Before and two weeks after a booster dose of E-Z vaccine haemagglutinin inhibiting (HAI) antibodies will be compared in the blood of the two groups of children. Long term antibody and cytokine responses to measles antigen will be measured one year after the boost. We predict that antibody concentrations will be similar in the two groups two weeks after the boost and that cellular responses will also be similar one year later.</gtr:technicalSummary><gtr:fund><gtr:end>2008-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>9078</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Bandim Health Project (BHP)</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>nonspecific effects of measles vaccines</gtr:description><gtr:id>7057F940-D868-45F1-A3C8-F10C9DE859E7</gtr:id><gtr:impact>scientific papers produced as listed</gtr:impact><gtr:outcomeId>qJd3oUtJk9K-1</gtr:outcomeId><gtr:partnerContribution>field trials in guinea Bissau</gtr:partnerContribution><gtr:piContribution>advice on design of field trials, supervision of laboratory assays for measles antibody</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>OPTIMISE (11.1m euros across 18 participants)</gtr:description><gtr:end>2014-10-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>53F79CB1-A779-49C6-A07F-4BD74D7125F3</gtr:id><gtr:outcomeId>cMppzdwYSNW0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2010-11-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>non-specific effects of measles vaccines</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>941FDE84-A108-4EB5-A707-D91D2D1B017D</gtr:id><gtr:outcomeId>jQVmnPhKWPe</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>2BB8E2BE-251C-4249-AE0A-82D5386FE478</gtr:id><gtr:title>Protective efficacy of standard Edmonston-Zagreb measles vaccination in infants aged 4.5 months: interim analysis of a randomised clinical trial.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6b192bc6c0d5ee971d43f33211f67427"><gtr:id>6b192bc6c0d5ee971d43f33211f67427</gtr:id><gtr:otherNames>Martins CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>82EE5369CF2</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U190088488</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>D8F3A27D-084A-40BB-A046-087DACE23410</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>3.4  Vaccines</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>